Unmet Need
VCC-001, the most advanced product candidate demonstrated clinical efficacy and a favorable safety profile in several clinical trials. 1, 2, 3, 4 The availability of clinical data that have been obtained in >1000 patients reduces risk of failure of future clinical trials I.
Mechanism of Action: Inducing a specific immune response against
the patientʼs tumour based on the individual antigen profile
to enable the immune system to recognize and attack the tumour.
Only One In 10,000 Substances Tested In Research
Laboratories Will Eventually Become A Drug After About
12 Years. The Cost Is 1–1.5 Billion Us Dollars.
Phase III Clinical Study:
VCC-001 has already demonstrated significant
clinical efficacy in phase III in 553 patients with
RCC post-nephrectomy.
VCC-001 DEMONSTRATED favorable
safety profile in phase III
VCC-002 :Metastatic Renal Cell Carcinoma.
VCC-003: Colorectal Cancer
VCC-004: Lung Cancer
VCC-005: Bladder Cancer
1. Repmann et al., 2003 Anti Cancer Research 23: 969-974
2. Jocham et al., 2004 Lancet 363:594-99
3. Doehn et al., 2006 Supplement Journal of Urology 5(20): 286
4. May et al., 2009 Cancer Immunol Immunotherap 59(5):687-95